Cell MedX (CMXC) Advances the Power of Microcurrents
By RYAN ALLWAY November 29, 2016
Microcurrent therapy uses extremely low-level electrical currents that promote general wellness and alleviate complications associated with certain medical conditions. On a cellular level, the technology stimulates a dramatic increase in ATP (adenosine triphosphate) production and protein synthesis that accelerates healing and increases blood flow. This translates into decreased inflammation, reduced pain, and other beneficial effects for those suffering from a number of potentially serious health conditions.
This approach is a natural alternative to conventional therapies such as pharmaceuticals and surgical interventions. For example, using microcurrent therapies to reduce pain has the potential to reduce the excessive usage of opioid medications, as well as treat conditions for which there are no conventional therapies – such as fibromyalgia or diabetes – where existing standard-of-care options only slightly reduce complications.
In this article, we will look at how Cell MedX Corp. (CMXC) has improved upon microcurrent technology with eBalance Pro and its progress towards commercialization.
A Better Approach
The most common microcurrent therapy is known as a pulsed electrical magnetic field – or PEMF, which is applied to the skin to elicit a cellular response depending on the amplitude, frequency, and waveform. Since the late-1970s, the FDA has approved these kinds of devices to treat everything from non-union fractures to major depressive disorders, although their effectiveness in treating these conditions is widely documented, results tend to vary.
Cell MedX Corp. (CMXC) is pioneering a new microcurrent therapy device called eBalance that uses proprietary software to read the body’s response to the microcurrents being applied, and uses this information to fine-tune a range of electrical frequencies designed to target specific conditions. The company believes that its technology has the potential to address the complications associated with a growing list of medical conditions.
This list of conditions represents multi-billion dollar markets, of which a large percentage of the United States’ population suffers from daily, with few alternative treatment options.
Observational Studies & Clinical Trial
Cell MedX Corp. (CMXC) is initially focusing its clinical protocols on safely studying the effects of its eBalance Pro device on diabetes and related complications. The observations and testimonials resulting from the company’s early observations are currently being reported on Cell MedX’s website on an ongoing basis, but investors will have to wait for the results from its initial observational clinical trials to determine the efficacy profile anticipated for the technology.
Cell MedX plans to begin observational clinical trials early next year with the goal of obtaining Health Canada approval to use eBalance Pro as a medical device for the treatment of diabetes and related complications. While the company is moving to obtain approval from Health Canada, similar activities are under way in Europe and Asia, and as data becomes available management believes it will be able to more readily develop an FDA approval pathway for the U.S. marketplace.
Looking Ahead
Investors interested in the exploding wellness industry may want to take a closer look at Cell MedX Corp. (OTCQB: CMXC) given its unique approach to microcurrent therapies and its potential to address several multi-billion dollar market opportunities. With Canadian observational clinical trials set to begin shortly, the company is building a growing pipeline of catalysts that could drive value for shareholders over the long-term.
For more information, visit the company’s website at https://cellmedx.com/
Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. In particular, Cell MedX Corp. has not yet begun its clinical trials, which are pending Health Canada approval. There is no assurance that the results of Cell MedX Corp.’s clinical observational trials will be successful, or that it will be able to obtain licensing or approval from Health Canada, the FDA or any other regulatory agencies. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC has been compensated $1,000 for the production and dissemination of this article. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.
Source: http://analysis.secfilings.com/articles/130-cell-medx-cmxc-advances-the-power-of-microcurrents